Another Beginning for Cystic Fibrosis Therapy  

Oleh:

Davis, Pamela B.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 373 no. 03 (Jul. 2015), page 274-276.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Treatments for the fundamental defect in cystic fibrosis are beginning to come to fruition. Cystic fibrosis, an autosomal recessive disease of epithelial chloride transport, can be caused by more than 1000 mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). However, these mutations fall into six functional categories,1 which gives hope that therapies specific to particular mutant categories can be developed. The first success, ivacaftor, was approved by the Food and Drug Administration (FDA) in 2012 for treatment of the 4 to 5% of patients who have the Gly551Asp mutation in CFTR and later for patients with other mutations in which the protein reaches the plasma membrane but does not open appropriately. In patients with the Gly551Asp mutation, ivacaftor corrects the sweat chloride defect, improves pulmonary function and patient-reported respiratory symptoms, and results in substantial weight gain.2

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali